Heat Biologics
Heat Biologics is a biotechnology company focused on the field of cancer immunotherapy.
Business Model:
Revenue: $0
Employees: 1-10
Rankings
Industries / Tags:
Detailed Heat Biologics Information
Geographic Data
Address:
City: Chapel Hill
State: North Carolina
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$14M
Raised Total:$50M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) adjuvant technology for use in a number of oncology and infectious disease indications. Heat’s ImPACT therapy is a first-in-class fully human adjuvant system that functions as both an immune stimulator and an antigen-delivery system. ImPACT is rapidly applied to a selected off-the-shelf cancer cell line to effectively transform living tumor into powerful machines that “pump out” their full antigenic fingerprint to robustly stimulate the immune system against the targeted disease. ImPACT is applicable to a wide range of cancers as well as infectious diseases including HIV, HCV and malaria. Heat is currently in Phase II clinical trials with its first drug to treat Non Small Cell Lung Cancer (NSCLC) and plans to initiate clinical trials against additional cancers in 2012.
Contact Phone:
Contact Email:
Heat Biologics went public on 7/24/2013 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
7/24/2013
Ticker Symbol:
HTBX
IPO Price:
$10/share
Amount Raised:
$25M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 8/2014 | Post-IPO Debt | 1 | $7.5M |
Square 1 Bank Square 1 Bank |
5/2018 | Post-IPO Equity | $20.7M | 5/2012 | Series A | $2.8M | 11/2018 | Post-IPO Equity | $13.8M | 4/2013 | Private Equity Round | $5.1M | 11/2009 | Seed Round | $249.8k |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 12/2021 | Elusys Therapeutics |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
